Questions about adjuvant trastuzumab still remain.
- 1 January 2007
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 369 (9555) , 3-5
- https://doi.org/10.1016/S0140-6736(07)60004-X
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialThe Lancet, 2007
- How much will Herceptin really cost?BMJ, 2006
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006
- NICE discriminationJournal of Medical Ethics, 2005
- Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical TreatmentJournal of Clinical Oncology, 2005
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005